| Drug Name: | Sirolimus (53123-88-9) |
|---|---|
| PubChem ID: | 5284616 |
| SMILES: | C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC |
| InchiKey: | QFJCIRLUMZQUOT-HPLJOQBZSA-N |
| Therapeutic Category: | Anti-Bacterial Agents, Anti-Infective Agents, Antibiotics, Antifungal Agents, Antineoplastic Agents, Immunologic Factors, Immunosuppressive Agents |
| Molecular Weight (dalton) | : | 914.187 |
| LogP | : | 6.1806 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 13 |
| Hydrogen Bond Donor Count | : | 3 |
| Total Polar Surface Area | : | 195.43 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Distinctive Arrays Of Toxic Side Effects | phytohemagglutinin (P05088) | FK506 and CsA showed pharmacologic antaGOnism in inhibiting in vitro proliferation upon phytohemagglutinin@ anti-CD3 antibody@ and mixed lymphocyte reaction (MLR) stimulation by display distinctive arrays of toxic side effects [ ADR Type 1 ] | Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2 |
| Human Natural Killer (Nk) Cell Cytotoxicity | Interleukin-2 (P60568) | The activation of human natural killer (NK) cell cytotoxicity by interleukin 2 (IL-2). [ ADR Type 5 ] | Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2 |
| Nephrotoxicity | Calcineurin (P63098) | Cyclosporine A and FK506 nephrotoxicity may reflect renal-specific functions of calcineurin [ ADR Type 2 3 ] | Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin |
| Nephrotoxicity | Interleukin-2 (P60568) | The target of the FKBP12-rapamycin complex is TOR@ a lipid and protein kinase homolog that is likely to be required for T-cell proliferation in response to interleukin-2@which may lead to nephrotoxicity [ ADR Type 5 ] | Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin |
| Nephrotoxicity | vasodilator prostaglandins (P00059) | The target of the FKBP12-rapamycin complex is TOR, a lipid and protein kinase homolog that is likely to be required for T-cell proliferation in response to interleukin-2,which may lead to nephrotoxicity [ ADR Type 5 ] | Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|---|---|
| Grapefruit Juice | Bone Marrow Toxicity | Grapefruit-medication interactions: forbidden fruit or avoidable consequences? |
| Grapefruit Juice | Nephrotoxicity | Grapefruit-medication interactions: forbidden fruit or avoidable consequences? |
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category